Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Hemodynamic Dose-Escalation Study of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension
2018-003414-40Phase 2Completed
- Sponsor
- Liquidia Corporation
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of treprostinil in pulmonary arterial hypertension (PAH) (4 arms), sponsored by Liquidia Corporation. Primary endpoint: Hemodynamic dose-response to LIQ861. Started Nov 2018; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2018-003414-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003414-40.